Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Other Events
On August 7, 2019, Neuralstem, Inc. (the “Company”) announced that on August 6, 2019, it received a letter from the Office of General Counsel of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that the Nasdaq Hearings Panel has granted the Company’s request for continued listing of the Company’s stock on the Nasdaq Stock Market.
A copy of the press release is attached to this report as Exhibit 99.01.
|99.01||Press Release dated August 7, 2019|
Neuralstem, Inc. Exhibit
EX-99.01 2 exh_9901.htm EXHIBIT 99.01 Exhibit 99.01 Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing GERMANTOWN,…
To view the full exhibit click
About Neuralstem, Inc. (NASDAQ:CUR)
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.